Showing results (1741-1750 of 1,938) with videos related to

Sort By:
Pageof 194
JAMA Surgery|January 10, 2024
Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node StatusRoger Olofsson Bagge, Rasmus Mikiver, Michael A Marchetti, et al.
Journal of the American College of Surgeons|February 20, 2017
Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity SarcomaJohn E Mullinax, Hidde M Kroon, John F Thompson, et al.
Human Genetics|December 22, 2004
Oligogenic combinations associated with breast cancer risk in women under 53 years of ageChristopher E Aston, David A Ralph, Dominique P Lalo, et al.
Nature Communications|December 3, 2014
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanomaGeorgina V Long, Carina Fung, Alexander M Menzies, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 4, 2025
Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node-positivity in melanoma patientsJohn F Thompson, Roger F Uren, Kevin London, et al.
International Journal of Molecular Sciences|October 13, 2021
Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick MelanomasCanan Güvenç, Asier Antoranz, Anna Szumera-Ciećkiewicz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2022
Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patientsMary-Ann El Sharouni, Richard A Scolyer, Carla H van Gils, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damageVictoria J Mar, Stephen Q Wong, Jason Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2017
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK InhibitorsHojabr Kakavand, Robert V Rawson, Gulietta M Pupo, et al.
Nature Cancer|December 11, 2020
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrenceWiebke Pruessmann, Julie Rytlewski, James Wilmott, et al.
Pageof 194